Back
24 Feb 2026
Pfizer secures China rights to obesity drug in US$495 mil deal
Summary
Pfizer acquired exclusive rights to commercialize the obesity drug ecnoglutide in China from Hangzhou Sciwind Bioscience Co. The US$495 million deal includes an upfront payment and milestone-based fees. This partnership supports Pfizer’s strategic planning in the metabolic space and aligns with China’s Healthy China campaign.